Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 13,625 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Breast Neoplasms
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Background hormonal therapy; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 11
States / cities: Bakersfield, California • La Jolla, California • Aurora, Colorado + 8 more

Conditions: Acanthosis Nigricans, Hyperinsulinemia, Spectroscopic Analysis
Interventions: Metformin, Dietary Modification; Drug · Behavioral
Lead sponsor: Henry Ford Health System; Other
Eligibility: 11 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Breast Cancer
Interventions: Surveillance Brain MRI, Standard of Care Brain Imaging; Diagnostic Test
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Miami, Florida • Tampa, Florida

Conditions: Androgenetic Alopecia
Interventions: TopHat 655 rejuvenation system, Laser and/or Light Hair Rejuvenation System; Device
Lead sponsor: Apira Science, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Hoboken, New Jersey • New York, New York • Rochester, New York + 1 more

Conditions: Melanoma
Interventions: Blood Sample Collection; Other
Lead sponsor: Exact Sciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 36
States / cities: Little Rock, Arkansas • Laguna Hills, California • Palm Springs, California + 32 more

Conditions: Breast Cancer
Interventions: E-Talkcare, Usual Care; Other
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Cancer
Interventions: Brain Fitness Program (BFP); Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Tobacco Dependence
Interventions: placebo, varenicline; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers, Breast Cancer, Metastatic
Interventions: Blood draw; Diagnostic Test
Lead sponsor: Angle plc; Industry
Eligibility: 22 Years and older · Female only
Enrollment: 421 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • Chicago, Illinois • Rochester, New York + 1 more

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 1,353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 48
States / cities: Glendale, Arizona • Phoenix, Arizona • Bakersfield, California + 43 more

Conditions: Carcinoma, Non-Small-Cell Lung, Breast Neoplasms
Interventions: TR(ACE) Assay Testing; Device
Lead sponsor: Biological Dynamics; Industry
Eligibility: 21 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 16
States / cities: Encinitas, California • Oceanside, California • Santa Monica, California + 13 more

Conditions: Breast Cancer, Ductal Carcinoma in Situ
Interventions: MRI; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 59 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2025
U.S. locations: 3
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York

Conditions: Hormone Receptor-Positive Breast, Gynecologic, Desmoid, Hormone Receptor-Positive Neoplasms
Interventions: Z-Endoxifen; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hereditary Angioedema (HAE)
Interventions: CINRYZE; Biological
Lead sponsor: Shire; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 8
States / cities: Colorado Springs, Colorado • Tampa, Florida • Chevy Chase, Maryland + 5 more

Conditions: Hypoxemia, Pulse Oximetry, Skin Pigment
Interventions: Observational; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 757 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non-Melanoma Skin Cancer (NMSC)
Interventions: OFDI; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Saline, 0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 79 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5
Interventions: AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, Camizestrant; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Oklahoma City, Oklahoma + 1 more

Conditions: Solid Tumors and Hematologic Malignancy
Interventions: INCB054329 Monotherapy; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more

Conditions: Melanoma
Interventions: Pembrolizumab and high dose interferon alfa-2b (HDI); Drug
Lead sponsor: Yana Najjar; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Buffalo, New York • Pittsburgh, Pennsylvania

Conditions: Rosacea
Interventions: Roflumilast Cream; Drug
Lead sponsor: Dermatology Consulting Services, PLLC; Network
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Solid Tumor Cancer, Solid Tumor, Unspecified, Adult, Colorectal Carcinoma, Colorectal Carcinoma (CRC), Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Pancreatic Cancer, NSCLC, Mesothelioma, Ovarian Cancer, Ovarian Carcinoma, Head and Neck (HNSCC), Head and Neck Cancer, Renal Cell Carcinoma (Kidney Cancer), Triple Negative Breast Cancer (TNBC)
Interventions: No additional intervention administered in this long term follow-up study; Other
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2040
U.S. locations: 3
States / cities: Gilbert, Arizona • Rochester, Minnesota • New York, New York

Conditions: Breast Cancer
Interventions: CARE, CARE + COACH; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: Female only
Enrollment: 323 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Whiteriver, Arizona

Conditions: Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer, Virtual Reality, Trastuzumab
Interventions: Cardiovascular Health Education and Gaming through Virtual Reality; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Richmond, Virginia

Search by objective public record fields.

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

Spectroscopic and Colorimetric Analysis of Acanthosis Nigricans in Patients With Hyperinsulinemia

Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer

Treatment of Androgenetic Alopecia in Males and Females

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma

Web-Based Communication Education for Breast Cancer Survivorship Care

An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer Survivors

Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)

Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

TR(ACE) Assay Clinical Specimen Study

Breast MRI as a Preoperative Tool for DCIS

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

Pulse Oximetry Errors in Hospitalized Patients Across Varying Skin Pigmentation

Optical Frequency Domain Imaging for Non-melanoma Skin Cancers

Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b

Evaluation of the Safety and Efficacy of Topical Roflumilast Cream in the Treatment of Facial Papulopustular Rosacea

A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products

Developing and Evaluating Culturally Relevant Interventions to Improve Breast Cancer Screening

Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab